563 related articles for article (PubMed ID: 19397417)
1. Vero cell platform in vaccine production: moving towards cell culture-based viral vaccines.
Barrett PN; Mundt W; Kistner O; Howard MK
Expert Rev Vaccines; 2009 May; 8(5):607-18. PubMed ID: 19397417
[TBL] [Abstract][Full Text] [Related]
2. Continuous cell lines as a production system for influenza vaccines.
Genzel Y; Reichl U
Expert Rev Vaccines; 2009 Dec; 8(12):1681-92. PubMed ID: 19943763
[TBL] [Abstract][Full Text] [Related]
3. Suspension-Vero cell cultures as a platform for viral vaccine production.
Paillet C; Forno G; Kratje R; Etcheverrigaray M
Vaccine; 2009 Oct; 27(46):6464-7. PubMed ID: 19559123
[TBL] [Abstract][Full Text] [Related]
4. Use of MDCK cells for production of live attenuated influenza vaccine.
Liu J; Shi X; Schwartz R; Kemble G
Vaccine; 2009 Oct; 27(46):6460-3. PubMed ID: 19559113
[TBL] [Abstract][Full Text] [Related]
5. A cell culture (Vero)-derived H5N1 whole-virus vaccine induces cross-reactive memory responses.
Ehrlich HJ; Müller M; Fritsch S; Zeitlinger M; Berezuk G; Löw-Baselli A; van der Velden MV; Pöllabauer EM; Maritsch F; Pavlova BG; Tambyah PA; Oh HM; Montomoli E; Kistner O; Noel Barrett P
J Infect Dis; 2009 Oct; 200(7):1113-8. PubMed ID: 19712040
[TBL] [Abstract][Full Text] [Related]
6. Cell culture-derived influenza vaccines from Vero cells: a new horizon for vaccine production.
Montomoli E; Khadang B; Piccirella S; Trombetta C; Mennitto E; Manini I; Stanzani V; Lapini G
Expert Rev Vaccines; 2012 May; 11(5):587-94. PubMed ID: 22827244
[TBL] [Abstract][Full Text] [Related]
7. The present status of rabies vaccine development and clinical experience with rabies vaccine.
Roumiantzeff M
Southeast Asian J Trop Med Public Health; 1988 Dec; 19(4):549-61. PubMed ID: 3070767
[TBL] [Abstract][Full Text] [Related]
8. A novel mammalian cell (Vero) derived influenza virus vaccine: development, characterization and industrial scale production.
Kistner O; Barrett PN; Mundt W; Reiter M; Schober-Bendixen S; Eder G; Dorner F
Wien Klin Wochenschr; 1999 Mar; 111(5):207-14. PubMed ID: 10226351
[TBL] [Abstract][Full Text] [Related]
9. Polio and rabies vaccines produced in continuous cell lines: a reality for Vero cell line.
Montagnon BJ
Dev Biol Stand; 1989; 70():27-47. PubMed ID: 2759353
[TBL] [Abstract][Full Text] [Related]
10. Systematically experimental investigation on carcinogenesis or tumorigenicity of VERO cell lines of different karyotypes in nude mice in vivo used for viral vaccine manufacture.
Zhang DL; Ji L; Li LJ; Huang GS
Yi Chuan Xue Bao; 2004 Jul; 31(7):647-60. PubMed ID: 15473315
[TBL] [Abstract][Full Text] [Related]
11. [Study on a purified and inactivated Japanese encephalitis vaccine prepared on Vero cells using SA14-14-2 attenuated virus strain].
Yao Z; Dong G; Yu Y
Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 1999 Jun; 13(2):191-3. PubMed ID: 12569794
[TBL] [Abstract][Full Text] [Related]
12. [Preparation of vero cell-adapted influenza H5N1 virus strain by genetic reassortment].
Shen J; Sun MB; Ma L; Song SH; Li WD; Jiang SD; Yang JS; Liao GY
Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2010 Apr; 24(2):119-21. PubMed ID: 21110431
[TBL] [Abstract][Full Text] [Related]
13. Vero cell technology for rapid development of inactivated whole virus vaccines for emerging viral diseases.
Barrett PN; Terpening SJ; Snow D; Cobb RR; Kistner O
Expert Rev Vaccines; 2017 Sep; 16(9):883-894. PubMed ID: 28724343
[TBL] [Abstract][Full Text] [Related]
14. Assessment of immunogenic potential of Vero adapted formalin inactivated vaccine derived from novel ECSA genotype of Chikungunya virus.
Tiwari M; Parida M; Santhosh SR; Khan M; Dash PK; Rao PV
Vaccine; 2009 Apr; 27(18):2513-22. PubMed ID: 19368794
[TBL] [Abstract][Full Text] [Related]
15. In vitro potency assay for yellow fever vaccines: comparison of three vero cell lines sources.
Fournier-Caruana J; Poirier B; Garnier F; Fuchs F
Biologicals; 2000 Mar; 28(1):33-40. PubMed ID: 10799054
[TBL] [Abstract][Full Text] [Related]
16. Optimization of virus yield as a strategy to improve rabies vaccine production by Vero cells in a bioreactor.
Trabelsi K; Rourou S; Loukil H; Majoul S; Kallel H
J Biotechnol; 2006 Jan; 121(2):261-71. PubMed ID: 16153733
[TBL] [Abstract][Full Text] [Related]
17. Development of a Vero cell-derived influenza whole virus vaccine.
Kistner O; Barrett PN; Mundt W; Reiter M; Schober-Bendixen S; Eder G; Dorner F
Dev Biol Stand; 1999; 98():101-10; discussion 111. PubMed ID: 10494963
[TBL] [Abstract][Full Text] [Related]
18. [Passage adaptability of candidate strains for hemorrhagic fever with renal syndrome purified vaccine in Vero cells and their immunogenicity].
Chen W; Xue CF; Liu JQ; Li ZY; Fan YX; Xu L; Liao H
Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2003 Jun; 17(2):129-32. PubMed ID: 12869992
[TBL] [Abstract][Full Text] [Related]
19. New viral vaccines.
Arvin AM; Greenberg HB
Virology; 2006 Jan; 344(1):240-9. PubMed ID: 16364754
[TBL] [Abstract][Full Text] [Related]
20. Suitability of PER.C6 cells to generate epidemic and pandemic influenza vaccine strains by reverse genetics.
Koudstaal W; Hartgroves L; Havenga M; Legastelois I; Ophorst C; Sieuwerts M; Zuijdgeest D; Vogels R; Custers J; de Boer-Luijtze E; de Leeuw O; Cornelissen L; Goudsmit J; Barclay W
Vaccine; 2009 Apr; 27(19):2588-93. PubMed ID: 19428865
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
